Skip to main content
Home

Leading research for life changing results

  • Our Role & Impact
    • About HMRI
    • Our People
    • Research Funded through HMRI
    • Foundations
      • HMRI Foundation
      • HMRI Sydney Foundation
      • HCRF
      • HTRF
      • Mark Hughes Foundation
      • Borne HMRI
    • Awards and Recognition
      • Researcher Awards
      • HMRI Exceptional Service
    • Our Partnerships
    • Governance
  • Medical Research
    • Research
    • Researchers
    • News & Articles
    • Participate In Research
    • Coronavirus (COVID-19)
  • Support HMRI
    • Donate Now
    • Your Impact
    • Ways to Donate
    • Fundraise
    • Bequests
    • Volunteer
    • Company Donors
    • Events
      • Upcoming Events
      • Past Events
  • For Researchers
    • HMRI Connect
    • Clinical Trials Unit
    • Promote Your Work
    • Research Project Support
    • Facilities & Equipment
    • Funding Support
    • Register with HMRI
  • Connect
    • Contact Us
    • Sign up for updates
    • Connect Intranet
  1. Home
  2. Search Results

Search Results

  • All (21) Remove All (21) filter
  • News & Articles (10)
  • Researcher Profiles (6)
  • Research (5)

Search found 21 items

All
Tests show potential for medicinal cannabis to kill cancer cells
Category: News & Articles
... need to understand the mechanism so we can find ways to add other drugs that amplify the effect, and week by week we’re getting more ...
HMRI 2010/2011 Project Grant Recipients
Category: News & Articles
... focused on a range of chemicals released from immune cells. In fact drugs that target one of these chemicals (TNFά) offer some relief to ... ineffective. The design of new and more effective anti-arrhythmic drugs is hampered by the lack of an understanding how an ideal drug ... anti-arrhythmic drug strategy; and be a foundation for the design of drugs to control ventricular arrhythmias in coronary artery disease.   ...
Targeting a tumour suppressor for new cancer therapies
Category: Research
... with loss of PPP2R2A are highly sensitive to two specific classes of anticancer drugs: PARP inhibitors, and PP2A activating drugs. This project will test whether tumours with PPP2R2A loss will ...
HMRI wins $73K equipment grant from Ramaciotti
Category: News & Articles
... to assist cancer researchers in the development of new anti-cancer drugs, ensuring the best outcomes for patients. The Ramaciotti ... to assist cancer researchers in the development of new anti-cancer drugs, ensuring the best outcomes for patients. The Ramaciotti ...
A new approach to treat acute myeloid leukaemia
Category: News & Articles
... off of PP2A in AML, the team are able to target this protein using drugs to restore PP2A activity, killing the tumour cells. Importantly it ...
Buyout signals hope for cancer therapy
Category: News & Articles
... benefit patients. “There’s still a lot of unmet need. KEYTRUDA drugs currently have response rates in the order of 30 to 50 per cent ...
FU-SAFE: Individual Patient Data Meta-Analysis Evaluating the Link Between Dihydropyrimidine Dehydrogenase (DPD) Genotype and/or Phenotype, and Severe Fluoropyrimidine-Related Toxicity
Category: Research
Fluoropyrimidines (5-FU and capecitabine) are anticancer drugs commonly used in a range of cancers including oesophageal, gastric ...
Prostate Cancer
Category: Research
... In 2014, researchers reported a new combination of anti-cancer drugs and radiation which was successful in treating men with ...
Danielle Bond
Category: Researcher Profiles
... and change over time. Ultimately, my goal is to design more effective drugs that prevent cancer or prevent it coming back in patients after ... cancer patients, in order to better understand the actions of these drugs and to identify markers that predict treatment response. This will ...
RADAR detects new prostate cancer treatment
Category: News & Articles
... findings hold true at the 10-year patient follow-up in 2017. As all drugs used in the trials are already in widespread use, these treatments ...
  • 1
  • 2
  • 3
  • View Research & Diseases
  • News & Articles
  • Careers
  • Site Map
  • Privacy Policy
  • HMRI Connect
  • Stay Connected
  • HUNTER MEDICAL RESEARCH INSTITUTE ABN 27 081 436 919 Phone (02) 4042 0000 Donation Hotline 1300 993 822
  •  
  • Copyright © All rights reserved
  • Tata Consultancy Services